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Aim: TRPM4 is a Ca2+-activated non selective channel expressed in atrium, 
conduction tissue but not in ventricle. Recently, several studies demonstrated that 
gain-of-function mutations in TRPM4 induced conduction disturbances in human. 
Nevertheless, the role of the TRPM4 channel in heart physiology remains to be 
elucidated. Here, we took advantage of a mouse in which Trpm4 gene is invalidated 
(Trpm4-/-) to investigate the effect of TRPM4 channel in heart physiology in comparison 
with Trpm4+/+ mice.
Results: We demonstrated that Trpm4-/- mice displayed increased left ventricle 
(LV) wall thickness and dilation, associated to better stroke volume and cardiac output, 
suggesting eccentric hypertrophy. This higher LV mass was due to an increase of cellular 
density. To link myocellular density to proliferation, hyperplasia was assessed in neonate 
hearts. Positive mitotic nuclei were 3-fold increased in Trpm4-/- mice in ventricle but 
not in auricle. In order to determine the effect of eccentric hypertrophy in electrical 
propagation, we performed electrocardiograms (ECGs) analysis in freely moving mice. 
Trpm4-/- mice exhibited multilevel blocks in surface ECGs, validated by intracardiac 
explorations, associated to ectopic atrial activities. While the increase in cellular density 
could explain infrahisian conduction lengthening, it did not in suprahisian level. However, 
we showed a mRNA level increased of connexin 30.2, known to decelerate infl ux. We 
also demonstrated that atropine reduced Luciani-Weckenbach atrio-ventricular blocks, 
suggesting parasympathetic overdrive. We fi nally performed action potential (AP) 
measurement in cardiomyocytes from atria and left ventricle using the patch-clamp 
technique. We showed that Trpm4-/- atrial cardiomyocytes displayed shorter AP whereas 
there is no difference in ventricular cardiomyocytes.
Conclusion: TRPM4 seems to play multiple roles in the heart, including the 
regulation of heart size, conduction and cellular electrical activity. 
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CASK, a new partner of sodium channel Nav1.5 in the heart
Catherine Eichel, Florent Louault, Gilles Dilanian, Alain Coulombe, Stéphane 
Hatem, Elise Balse
Inserm UMRS956-UPMC, Paris, France
MAGUK proteins are implicated in the anchoring and scaffolding of macromole-
cular complex in the sarcolemma. CASK differs from other MAGUK by an N-terminal 
calcium/calmodulin-dependant protein kinase domain, a single PDZ domain and its 
nuclear translocation. However, little is known on CASK in the heart except that the 
gene is expressed. We found that CASK was expressed at a protein level in rat and 
human cardiomyocytes. Immunostainings of myocardial cryosections revealed that 
CASK belongs to the costamere at the lateral membrane where it colocalized with 
syntrophin/dystrophin but not with vinculin, two components of adhesion costamere 
complexes. In MDX mice hearts which lacks dystrophin, CASK was no longer expressed 
at the lateral membrane, confi rming that CASK is a part of the syntrophin/dystrophin 
costameric complex. Moreover, CASK and dystrophin co-precipitated. We previously 
showed that two pools of Nav1.5 channels are present in cardiomyocytes: one at the 
intercalated discs interacting with the MAGUK, SAP97 and a second at the lateral 
membrane interacting with the syntrophin/dystrophin complex. Here, we examined 
whether CASK could be implicated in the targeting of Nav1.5 channels at the lateral 
membrane. First, GST pull down experiments performed on heart lysat showed that 
CASK interacts with Nav1.5. Second, immunostainings revealed that CASK and 
Nav1.5 colocalizes at the lateral membrane of myocytes. Third, in a HEK cell line 
stably expressing Nav1.5 channels, CASK silencing enhanced sodium current (INa) 
while CASK overexpression decreased INa. In cultured rat atrial myocytes silenced 
for CASK, INa was also enhanced.
Conclusion, CASK shows unique cell localization among the MAGUK family 
at the costamere level where it interacts with dystrophin. It is a new partner of the 
subpopulation of Nav1.5 channels of lateral membrane that inhibits their functional 
expression.
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Aberrant splicing of SCN5A and cardiac sodium current dysfunction in 
DMSXL transgenic mouse model of Myotonic Dystrophy
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Background: Myotonic dystrophy type 1 (DM1) cardiac manifestations include 
commonly cardiac arrhythmias and rarely dilated cardiomyopathy. Beyond the CTG 
expansion, the mechanisms involved are unknown. Similar phenotypes have been 
described in cardiac sodium channelopathies and referred as overlap syndromes. 
Here we tested the hypothesis that abnormalities in the cardiac sodium current are 
involved DM1. 
Methods: In a transgenic mouse model of DM1 reproducing the CGT expansion, 
we performed at 3 and 8 months: i) surface electrocardiograms (ECG); and ii) cardiac 
echocardiography with analysis of tissular velocities and strain rate before and after 
administration of the sodium current blocker fl ecainide. Ventricular action potentials 
were recorded using microelectrode technique, and sodium current was recorded 
using whole cell patch-clamp technique. Tissular slices of ventricles were stained 
with Nav1.5 antibody, and picrosirius red to measure cardiac fi brosis. We studied 
SCN5A splicing on myocardial tissue.
Results: At 3months DM1 and WT mice had similar ECG and cardiac echo at 
baseline. Flecainide injection lowered signifi cantly more the tissular velocities and strain 
rate in DM1 mice. At 8 months, tissular velocities and strain rate were slower in DM1 
mice than in WT at baseline and fl ecainide injection induced bradyarrhythmias in 60% 
of DM1 mice vs none in WT (p< 0.05). In 8 months mice AP recordings showed that 
the maximum upstroke velocity was slower in DM1 ventricular myocytes (dV/dtmax: 
99±32 vs 116±34V/s; p=0.03). The kinetics of sodium current inactivation were faster 
in DM1 (T1/2, (-20 mV): 1.4±0.5 vs 1.8±0.4 ms; p=0.01). Ventricular staining showed 
similar Nav1.5 distribution in DM1 and WT, with no signifi cant fi brosis. We found 
abnormal splicing of SCN5A exon 18, which was truncated.
Conclusions: In an original mouse model of DM1, we provided evidences for 
alterations of sodium current that could contribute to both electrical disturbances and 
ventricle dysfunction and may be related to missplicing of SCN5A. DM1 could be 
another example of overlap syndrome due to sodium channelopathy. 
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ejection fraction, which was not ameliorated by leptin treatment. Action potential 
duration (APD) was prolonged in TAC animals at all repolarization periods, and 
frequently presented EADs. At 50% of repolarization, Leptin treatment reduced the 
DPA prolongation in TAC animals. This was correlated with a decrease in the potassium 
current IKs in HF. Thus although leptin did not ameliorated the cardiac function 
assessed by echocardiography, it did ameliorated electrophysiological remodeling.
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Oxidation of DHA is responsible for its anti-arrhythmic effects on mouse 
ventricular myocytes
Jérôme Roy 
Inserm U1046, Montpellier, France
Since forty years, it is known that long-chain polyunsaturated fatty acids of the 
series n-3 (PUFAs) have cardioprotective effects by preventing cardiac arrhythmias. 
The main PUFAs are eicosapentaenoic acid (C20:5 n-3, EPA) and docosahexaenoic 
acid (C22:6 n-3, DHA) that are highly peroxidable due to the presence of the skipped 
dienes. The effects of n-3 PUFA on cardiac function are still debated, notably because 
of the lack of information on the mechanisms involved. For example, it is not really 
known which the active lipid is: the PUFA or one of its oxygenated metabolites. A diet 
enriched in n-3 PUFAs (mainly fi sh-based), leads to enrichment in these fatty acids of 
cardiac cell membranes. Our hypothesis is that, during an infarct, the oxidative stress 
and the generation of reactive oxygen species might be responsible for an oxidation of 
membrane-bound PUFAs and the oxygenated metabolites generated might modulate 
the activity of ionic channels to exert anti-arrhythmic effects. We thus decided to 
investigate the infl uence of the peroxidation of DHA on its potentially anti-arrhythmic 
properties. In this study, we applied DHA free acid or DHA methyl ester (ME) (less 
sensitive to peroxidation) on freshly isolated mouse ventricular myocytes without or 
with α-tocopherol (Vitamin E, to prevent oxidation) or hydrogen peroxide (to enhance 
oxidation). We investigated, using a Photometric system (IonOptix®), calcium transients 
(using the ratiometric calcium fl uorescent dye Indo-1) and cell shortening of electrically 
stimulated myocytes. By stimulating β-adrenergic pathways with 10 nM isoproterenol, 
it is also possible to observe the appearance of arrhythmic events. We observed that 
DHA free acid reduced the percentage of arrhythmic cells but not DHA ME. These 
effects of DHA are correlated with the peroxidation of the fatty acid since α-tocopherol 
prevented the anti-arrhythmic effects while hydrogen peroxide enhanced them. These 
results suggest thus that rather than DHA itself, it is the oxygenated metabolites derived 
from DHA that are potentially anti-arrhythmic.
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Background: Sudden cardiac death (SCD) is principally due to ventricular 
arrhythmia (VA) occurring during the acute phase of ST elevation myocardial infarction 
(STEMI). In this context, many studies have shown the benefi t to use aldosterone 
blockers. However, actually the mechanisms remain unknown. We propose a new 
in vitro model using rabbit ventricle, mimicking the border zone between a normal 
zone (NZ) submitted to normoxia and an altered zone (AZ) submitted to an ischemia 
followed by a reperfusion, to study electrophysiological effects induced by aldosterone 
and potassium canrenoate. 
Method and Results: During simulated ischemia and on account of an increase of 
the action potential duration dispersion at 90% (APD90) between NZ and AZ, aldosterone 
increased VA occurrence. These deleterious effects were prevented by adding potassium 
canrenoate which also increased conduction block occurrence. 
Conclusion: Aldosterone increased APD90 dispersion between NZ and AZ and 
VA occurrence. These results support recent clinical studies underlying an interest in 
precocious aldosterone blockade in STEMI context.
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Leiden, Pays-Bas – (5) Université de Lausanne, Institut de pathologie, Lausanne, 
Suisse
Background: The sodium channel Na
V
1.5 initiates the cardiac action potential 
(AP) and is essential for conduction. The last three residues of Na
V
1.5 (Ser-Ile-Val) 
constitute a PDZ domain-binding motif (SIV) that interacts with PDZ proteins such 
as syntrophin and SAP97, at different locations of the cardiomyocyte, defi ning distinct 
subsets of Na
V
1.5 multi-protein complexes. Here, we investigated the in vivo role of 
this Na
V
1.5 SIV motif by characterizing mice with a truncation of this motif (ΔSIV), 
and screening for genetic variants in arrhythmia patients.
Methods and Results: Using a proximity ligation assay, we observed loss of 
interaction between Na
V
1.5 and syntrophin at lateral membranes of cardiomyocytes 
that was verifi ed in immunostainings to result from loss of lateral membrane Na
V
1.5 
expression. This was consistent with a 60% decrease in sodium current (I
Na), recorded 
at the lateral membrane of cardiomyocytes. However, Na
V
1.5 staining remained at 
intercalated discs (ID) and T-tubules, and no decrease was observed in I
Na recorded 
at the ID. Western blots of ΔSIV hearts displayed reduced levels of Na
V
1.5 which 
corresponded to a 35% decrease in cardiomyocyte whole-cell I
Na and AP upstroke 
velocity. Epicardial mapping of ΔSIV hearts displayed decreases in conduction velocity 
(CV) that manifested as prolongation of the QRS interval in ECGs. Transversal CV was 
preferentially affected. Furthermore, an Na
V
1.5 mutation in the SIV motif (p.V2016M), 
which was found in a Brugada Syndrome patient, displayed decreased I
Na and surface 
expression in transfected HEK293 cells. Pull-down experiments showed that V2016M 
disrupts interaction of Na
V
1.5 with SAP97. 
Conclusions: These data refl ect the in vivo signifi cance of the PDZ domain-binding 
motif of Na
V
1.5 in protein expression and cardiac function. The data support the model 
of distinct pools of Na
V
1.5 which are differentially regulated by interacting proteins 
that reside in separate membrane compartments of the cardiac cell. 
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Leptin treatement modulates electrophysiological remodeling in experimental 
heart failure
Alejandro Dominguez-Rodriguez (1), Nieves Gomez Hurtado (2), Philippe 
Mateo (1), Ana Maria Gomez (1), Carmen Delgado (2), Jean-Pierre Benitah (1) 
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Obesity has been established as a risk factor for the development of heart failure 
(HF). The role of adipose tissue with its secretory products (adipokines) as an active 
endocrine organ is gaining importance in the investigation of obesity-associated 
diseases. One of the adipokines that has been postulated as a link between obesity and 
HF is leptin. Leptin is a 16-kDa adipocyte-derived protein hormone, encoded by the ob 
(obesity) gene. Investigation into whether leptin exerts benefi cial or detrimental effects 
on cardiovascular function has yielded paradoxical observations. Here we analyzed 
leptin effects on experimental HF. Mice were subjected to thoracic aortic stenosis 
(TAC) to induce HF or to sham-operation (controls). 3 weeks after surgery, each group 
was divided into 2 sub- groups. Osmotic minipumps were implanted subcutaneously 
to all, half of the animals fi lled with leptin and the other half with saline solution. 
3 weeks after initiation of treatment, animals were echocardiographically analyzed 
and then sacrifi ced for patch-clamp experiments. Action potentials were analyzed in 
current clamp mode and potassium currents in voltage clamp mode. Special attention 
was given to the appearance of Early After Depolarizations (EADs) and/or Delayed 
After Depolarizations (DADs). TAC procedure induced a signifi cant decrease in the 
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Mitochondrial sensitivity to ADP in permeabilized fi bers changed as a 
function of cardiac muscle compartments: left/right atria and ventricles 
of sheep heart
Mathilde Chapolard, Fanny Vaillant, Philippe Pasdois, Pierre Jaïs, Michel 
Haïssaguerre, Pierre Dos Santos, Philippe Diolez, Véronique Deschodt-Arsac
IHU Liryc – Université de Bordeaux, CRCTB – Inserm U1045, Pessac, France
Because of the balance between ATP supply and ATP demand, alterations in 
cardiac energetics potentially affect cardiac work and may explain pathologies. 
Neverthelesss energetics alterations in each compartment remain unknown. Since 
mitochondrial oxidative phosphorylation is the main process of energy supply, 
mitochondrial sensitivity to energetic intermediates (e.g. ADP) is here investigated 
in a compartment-specifi c way.
KmADP were obtained in sheep permeabilized fi bers of right and left ventricles 
and atria using O2 consumption measurements (OROBOROS Oxygraph-2k), carried 
out in Mir05 with glutamate (5 mM) and malate (2 mM), at 25°C. 
Basal respiration (V0) and maximal ADP-stimulated respiration (Vmax) were 
similar among atria or ventricles (mean V0=33±3.9 and mean Vmax=72 pmol.sec
-1.
mg-1 dry wt). Interestingly, KmADP were signifi cantly higher in atria, especially in 
right one, than in ventricles, that were consequently characterized by a 1.5 to 3-fold 
higher sensitivity to ADP compared to left and right atria.
In beating heart, for a given energy state of the cell, mitochondria are more 
responsive in ventricles than in atria and more responsive in the left than in the 
right atrium. Interestingly mitochondrial responsiveness is likely in adequation with 
requested work in each chamber of the healthy heart and may be closely related to 
the ventricle ability to withstand problems of arrhythmias.
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Dronedarone is superior to amiodarone in preventing ventricular arrhythmias 
in an in vitro model of “Border Zone”
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Background: Ventricular arrhythmias (VA) are the most important causes of mortality 
in patients with heart failure and within the fi rst days after ST elevation myocardial 
infarction. To date, amiodarone is the more effective antiarrhythmic drug (AAD) in these 
contexts but unfortunately, extra-cardiac side effects are limited its use. Dronedarone, a 
non-iodinated benzofuran derivative of amiodarone, has not been studied on ventricular 
cardiomyocytes and in the prevention of VA. We propose an in vitro model using rabbit 
ventricle, mimicking the “border zone” existing between normal and ischemic/reperfused 
regions, to study electrophysiological effects induced by dronedarone and amiodarone. 
Method and Results: Like amiodarone, dronedarone has multichannel blocking 
properties and affected action potential parameters and decreased spontaneous arrhyth-
mias occurrence. Both did not have proarrhythmic effects in this model. In comparison 
with amiodarone, dronedarone was superior in preventing spontaneous VA occurrence 
during both simulated-ischemia and reperfusion periods. Both dronedarone and 
amiodarone systematically induced conduction blocks during simulated ischemia period.
Conclusion: In this in vitro model mimicking the “border zone”, we have shown 
that dronedarone has electrophysiological effects comparable to those of amiodarone 
but was more effective than amiodarone in preventing VA occurrence. Dronedarone did 
not show proarrhythmics effects. Our data suggest that the acute effects of dronedarone, 
despite absence of iodine in its molecular structure, seem to be very similar to those 
of amiodarone in cardiac ventricle and so this AAD could be an interesting alternative 
to amiodarone in preventing VA, particularly on ischemic cardiomyopathy. These 
conclusions need to be confi rmed by clinical studies.
